A Phase 1 Study Of INO-A002 In Healthy Dengue Virus-Naive Adult

A Phase 1 Study Of INO-A002 In Healthy Dengue Virus-Naive Adult

Brief description of study

The main purpose of this study is to evaluate the tolerability and safety of escalating injection doses of ‘INO-A002” with Hylenex. Through these injections, we hope to see the resulting expression of the monoclonal antibody ZK190. Monoclonal antibodies are laboratory-produced molecules which serve as substitute antibodies and can enhance or mimic the immune system's attack on Zika. The monoclonal antibody ZK190 will target the envelope protein of Zika virus in order to prevent the virus in healthy adults.
 
Electroporation (EP) by the CELLECTRA 2000 device will be used to increase cellular uptake of “INO-A002”. EP has been shown to be an effective way to introduce DNA into cells and to increase the expression levels of antigens encoded by DNA. 

Detailed description of study

Treatment:
 
Before injection, temperature, blood pressure, heart rate (pulse) and weight will be collected, and a targeted physical examination will be performed. “INO-A002” will be injected intramuscularly followed by EP with the CELLECTRA 2000 device. Prior to injection, blood samples will be collected for CPK and urine samples will be collected for urinalysis and urine pregnancy test.
 
For this study, some possible side-effects include: mild to moderate administration site pain or swelling, fatigue or myalgia in the first few days following injection, and visible lesion or bruising at injection site.  
Your study nurse will inform you about the schedule of visits for the following months. 

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Healthy Volunteer
  • Age: Between 18 Years - 60 Years
  • Gender: All

Requirements to Enter Study:
·         18 to 60 years old
·         Women of child-bearing age potential must agree to use medically effective contraception (oral, barrier methods, spermicide, etc.) or have a partner who is sterile from enrollment to 6 months following the last injection
·         Sexually active men who are fertile must agree to use a barrier method of contraception for at least 6 months following the last injection
·         No history of dengue virus vaccination or illness
·         No plans to travel to Caribbean, Central or South America during the 6 months following the last injection
·         Must be willing to allow storage and future use of samples for Zika virus related research
·         Will remain in the Philadelphia area for 1 year following the last injection for study visits 

Updated on 10 Jul 2023. Study ID: 832135

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center